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Bisphosphonates are primary pharmacological agents against osteoclast-mediated bone loss and widely used in the clinical practice
for prevention and treatment of a variety of skeletal conditions, such as low bone density and osteogenesis imperfecta, and
pathologies, such as osteoporosis, malignancies metastatic to bone, Paget disease of bone, multiple myeloma, and hypercalcemia
of malignancy. However, long-term bisphosphonate treatment is associated with pathologic conditions including osteonecrosis
of the jaw, named BRONJ, which impaired bone regeneration process. Clinical management of BRONJ is controversy and
one recent approach is the use of platelet concentrates, such as Concentrated Growth Factors, alone or together with
biomaterials or antioxidants molecules, such as resveratrol. The aim of the present study was to investigate the in vitro effects
of Concentrated Growth Factors and/or resveratrol on the proliferation and differentiation of human osteoblasts, treated or not
with bisphosphonates. Human osteoblasts were stimulated for 3 days in complete medium and for 21 days in mineralization
medium. At the end of the experimental period, the in vitro effect on osteoblast proliferation and differentiation was evaluated
using different techniques such as MTT, ELISA for the quantification/detection of osteoprotegerin and bone morphogenetic
protein-2, immunohistochemistry for sirtuin 1 and collagen type I, and the Alizarin Red S staining for the rate of mineralization.
Results obtained showed that Concentrated Growth Factors and/or resveratrol significantly increased osteoblast proliferation and
differentiation and that the cotreatment with Concentrated Growth Factors and resveratrol had a protective role on osteoblasts
treated with bisphosphonates. In conclusion, these data suggest that this approach could be promised in the clinical management
of BRONJ.
1. Introduction
Bisphosphonates are primary pharmacological agents against
osteoclast-mediated bone loss promoting the apoptosis of
osteoclasts actively engaged in the degradation of mineral on
the bone surface. Bisphosphonates, such as zoledronic acid
or zoledronate, alendronate, and pamidronate, are important
inhibitors of bone resorption and are widely used for manag-
ing a variety of skeletal conditions characterized by increased
osteoclast-mediated bone resorption, including multiple
forms of osteoporosis (e.g., juvenile, postmenopausal, or se-
nile), osteogenesis imperfecta, Paget disease of bone, hyper-
calcemia, andmalignancymetastatic to bone. However, long-
term bisphosphonate treatment is associated with a rare but
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serious adverse event: osteonecrosis of the maxillary and
mandibular bones [1–3]. This condition is called bisphos-
phonate-related osteonecrosis of the jaw or BRONJ. It can be
described as a condition in which an area of jawbone is not
covered by the gums. The condition must last for more than
eight weeks in a person taking any bisphosphonate.When the
bone is left uncovered, it does not receive blood and begins
to die. Symptoms of BRONJ include exposed bone, localized
pain, swelling of the gum tissues and inflammation, and loos-
ening of previously stable teeth. The mechanism underlying
BRONJ has proved difficult to unravel and the three broad
categories of intervention include conservative approaches
(e.g., mouth rinse, antibiotics), surgical interventions, and
adjuvant nonsurgical strategies (e.g., hyperbaric oxygen ther-
apy, platelet concentrates, and laser application), which can
be used in combination [4]. All these approaches aim at bone
regeneration, which can be required in large quantity. Bone
regeneration is a complex, well-orchestrated physiological
process of bone formation, which involves different factors, a
number of cell types, and intracellular and extracellular
molecular-signaling pathways, with a definable temporal and
spatial sequence, in order to optimize skeletal repair and re-
store skeletal function.
Among the different strategies used to augment the im-
paired or “insufficient” bone regeneration process, one cur-
rent approach is the local application of growth factors
through the use of platelet concentrates, such asConcentrated
Growth Factors (CGF) [5, 6]. They are autologous prepa-
rations obtained from the patient’s own blood that is then
subjected to a specific and standardized protocol of centrifu-
gation [7, 8]. CGF represents the most recent concentrate,
developed by Sacco in 2006. Several data suggest that it
possesses a good regenerative capacity and versatility, having
a positive effect for sinus and alveolar ridge augmentation [9],
preimplant augmentation procedures [10], promotion of in
vitro proliferation, osteogenic maturation andmineralization
of mesenchymal stem cells, and healing of critical-size bone
defects in vivo [11], and promotion of in vitro periodontal lig-
ament stem cells proliferation [12]. The efficacy of this treat-
ment lies in the local delivery of awide range of growth factors
and proteins, mimicking and supporting physiologic wound
healing, reparative tissue process, and local, infiltration ther-
apy. CGF can be used alone or mixed with biomaterials such
as collagen, hydroxyapatite (HA),𝛽-tricalciumphosphate (𝛽-
TCP), calcium-phosphate cements, and also with antioxidant
molecules. Among these molecules, resveratrol is generally
known to be beneficial for human health, due to its anti-
inflammatory, antioxidant effects, and bone protective prop-
erties [13], that are mediated via the activation of sirtuin 1
(SIRT-1) [14]. It is a polyphenolic compound that occurs nat-
urally in mulberries, peanuts, grape and berry skins, and red
wine [15, 16]. Several biological effects of resveratrol have
been reported, including platelet aggregation attenuation
[17], cardiovascular protection [18, 19], anticancer activity
[20, 21], and neuroprotective effect [22]. Other studies show
that resveratrol stimulates in vitro osteoblast cells prolifer-
ation and differentiation [15, 23, 24] and prevented osteo-
porosis in ovariectomized rats [25, 26] and steroid-induced
osteonecrosis in a rabbit model [27].
Based on these considerations, the growth factors deliv-
ered by CGF and the antioxidant effect of resveratrol could
have a synergic role in bone deposition and protection against
the side effects of bisphosphonates. So, the aim of the present
study was to investigate the in vitro effect of treatment with
CGF and/or resveratrol on the proliferation (3 days) and
differentiation (21 days) of human osteoblast cells (HOB),
treated or not with bisphosphonates monitoring indicative
molecular recognisedmarkers, such asosteoprotegerin (OPG)
[28], bone morphogenetic protein-2 (BMP-2) [29], collagen
type I (Col I) [30], sirtuin 1 (SIRT-1) [31], and Alizarin Red S
staining [32] for calcium deposits.
2. Materials and Methods
2.1. Cell Culture. Human osteoblasts (HOB, PromoCell, Hei-
delberg, Germany) were grown in Osteoblast Growth Medi-
um (OGM; PromoCell, Heidelberg, Germany) constituted
by Osteoblast Basal Medium (OBM; PromoCell, Heidelberg,
Germany) supplemented with gentamicin/amphotericin B
(antibiotic/antifungal) and Supplement Mix (OGM Supple-
ment Mix; PromoCell, Heidelberg, Germany) containing
growth factors (not specified by the manufacturer) at 37∘C,
5% CO
2
, in a humidified atmosphere until they reached
about 80% confluence, changing the medium every 2 days.
Experiments were performed using cells between passages 3-
4. At confluence, HOB were passaged and seeded in 6-well
culture plates (Sarstedt, Nuembrecht, Germany). For short
time experiments (3 days), the cells were starved in OBM,
free of serum and growth factors, for 24 hours; at the end
of the starvation period, the medium was removed and the
different cell treatments were performed (Tables 1 and 2).
For long time experiments (21 days), the OGM was replaced
with the Osteoblast Mineralization Medium (OMM; Pro-
moCell, Heidelberg, Germany) and the cells were subjected
to different treatments (Table 3). The in vitro experiments
were performed in triplicate to ensure the reproducibility of
results.
2.2. Resveratrol and Bisphosphonates Preparation. Resvera-
trol with purity greater than 98%was purchased from Sigma-
Aldrich (Milan, Italy). A 1mM stock solution of resveratrol
was prepared in absolute ethanol and further diluted in cell
culture medium to prepare the final working concentration
of 10 𝜇M, determined by a preliminary evaluation of different
concentration (1, 5, 10, 25, and 50𝜇M) on cell viability using
MTT assay (Table 1) [33]. The maximum final content of
ethanol in cultures was less than 0,1%. As regards bisphos-
phonates, based on literature data, we chose alendronate (AL)
and zoledronate or zoledronic acid (ZOL). Both AL and ZOL
were purchased fromSigma-Aldrich (Milan, Italy), in a sterile
powder form. They were diluted in cell culture medium to
obtain the final working concentration of 5𝜇M [34]. All the
solutionswere filtered under a flow laminar cabinet before the
use.
2.3. CGF Preparation. CGF was obtained by a venous blood
sampling from three male adult volunteers, who gave their
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Table 1: Evaluation of working concentration for resveratrol (RSV) after 3 days of treatments using MTT assay.
Cell treatments—3 days Evaluation performed
Complete medium (OGM)—control
MTT for determination of resveratrol (RSV) working concentration
OGM + RSV 1 𝜇M (R1)
OGM + RSV 5 𝜇M (R5)
OGM + RSV 10 𝜇M (R10)
OGM + RSV 25 𝜇M (R25)
OGM + RSV 50 𝜇M (R50)
Table 2: Human osteoblast (HOB) treatments in complete medium (OGM) for 3 days.
Cell treatments—3 days Evaluation performed
Complete medium (OGM)—control
MTT
ELISA for
osteoprotegerin (OPG) and bone
morphogenetic protein-2
(BMP-2)
immunohistochemistry for
sirtuin 1 (SIRT-1) and collagen
type I (Col I)
OGM + RSV 10 𝜇M (R10)
OGM + AL 5 𝜇M (AL5)
OGM + ZOL 5 𝜇M (ZOL5)
OGM + AL 5 𝜇M +RSV 10 𝜇M (AL5 + R10)
OGM + ZOL 5 𝜇M +RSV 10 𝜇M (ZOL5 + R10)
OGM + CGF (CGF)
OGM + CGF + RSV 10𝜇M (CGF + R10)
OGM + CGF + AL 5 𝜇M (CGF + AL5)
OGM + CGF + ZOL 5 𝜇M (CGF + ZOL5)
OGM + CGF + RSV 10𝜇M + AL 5𝜇M (CGF + AL5 + R10)
OGM + CGF + RSV 10𝜇M + ZOL5 𝜇M (CGF + ZOL5 + R10)
Table 3: Human osteoblast (HOB) treatments in mineralization medium (OMM) for 21 days.
Cell treatments—21 days Evaluation performed
Osteoblast mineralization medium (OMM)—control
Alizarin Red S staining
ELISA for
osteoprotegerin (OPG) and bone
morphogenetic protein-2 (BMP-2)
OMM + RSV 10𝜇M (OMM + R10)
OMM + AL 5𝜇M (OMM + AL5)
OMM + ZOL 5 𝜇M (OMM + ZOL5)
OMM + AL 5𝜇M +RSV 10 𝜇M (OMM + AL5 + R10)
OMM + ZOL 5 𝜇M +RSV 10 𝜇M (OMM + ZOL5 + R10)
OMM + CGF(OMM + CGF)
OMM + CGF + RSV 10𝜇M (OMM + CGF + R10)
OMM + CGF + AL 5𝜇M (OMM + CGF + AL5)
OMM + CGF + ZOL 5 𝜇M (OMM + CGF + ZOL5)
OMM + CGF + RSV 10𝜇M + AL 5 𝜇M (OMM + CGF + R10 + AL5)
OMM+CGF + RSV 10𝜇M+ ZOL 5𝜇M (OMM+ CGF + R10 + ZOL5)
previous written consent, with no systemic disorders, smok-
ing, infections, nonsteroidal anti-inflammatory drug use, and
a haemoglobin level < 13,5 g/dl. Blood (9ml) was drawn
in each sterile Vacuette tube (Greiner Bio-One, GmbH,
Kremsmu¨nster, Austria) silicon coated as serum clot acti-
vator. These tubes were then immediately centrifuged using
a special machine (Medifuge MF200, Silfradent S.r.l., Forl`ı,
Italy). At the end of the centrifugation process, three blood
fractions were identified: (1) the upper layer, representing the
liquid phase of plasma named platelet poor plasma (PPP);
(2) the lower layer, at the bottom of the tube, consisting in
free red blood cells (RBC); (3) the middle layer, representing
the solid CGF, consisting in three fractions: the upper white
part (WP), the downer red part (RP), and the middle “buffy
coat” (BC), interface between white and red part [7, 8]. After
centrifugation, each CGF was removed from the tube, using
sterile tweezers, under a laminar flow cabinet. The solid CGF
was obtained by cutting and discarding the lower fraction of
the red part of CGF. Subsequently, each CGF was processed
in relation to the experimental protocols, as described in
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detail in the next paragraphs. The in vitro experiments were
performed in triplicate to ensure the reproducibility of re-
sults.
2.4. MTT Colorimetric Assay. At the end of the different
treatment performed for 3 days, MTT (Thiazolyl Blue Tetra-
zoliumBlue, Sigma-Aldrich,Milan, Italy, 5mg/ml)was added
to each well for 4 hours at 37∘C. The culture medium was
aspirated and the same quantity of DMSO was added to each
well. The plate was put on the shaker for 15 minutes and
after the supernatant was transferred to a 96-microplate well.
Colorimetric changes were quantified in a microplate reader
(Tecno-Lab S.r.l., Brescia, Italy) at a wavelength of 540 nm.
TheMTT assay was performed in triplicate and data obtained
were expressed as the percentage optical density relative to
the negative control of 100%.
2.5. Enzyme Linked Immunosorbent Assay (ELISA). To assess
the possible effect of resveratrol and/or CGF on osteoblasts
treated or not with bisphosphonates, a human osteoprote-
gerin (OPG) ELISA kit (LifeSpan Biosciences, Inc., Seattle,
USA) and a human bone morphogenetic protein-2 (BMP-
2) ELISA kit (R&D Systems Inc., Minneapolis, Minnesota,
USA) were used to detect, respectively, the levels of OPG
and the levels of BMP-2, in the cell supernatant. Briefly, cells
were seeded in 6 well plates and subjected to different treat-
ments, at different times, as reported in Tables 2 and 3. At
the end of the different treatments, the conditioned medium
was collected, centrifuged for 10min at 1000×g, and stored
at −80∘C until the OPG and BMP-2 concentration was mea-
sured using the specific ELISA kit, according to the manufac-
turer’s instructions.
2.6. Immunohistochemistry for Sirtuin 1 (SIRT-1) and Col-
lagen Type I (Col I). After the diverse treatments, their
effect on the sirtuin 1 (SIRT-1) expression and collagen
type I (Col I) production was investigated by immunohisto-
chemistry after 3 days of culture. The UltraVision Quanto
Detection SystemHorseradish Peroxidase (HRP;ThermoSci-
entific, Thermo Fischer Scientific, CA, USA) followed by
development with the chromogen substrate 3,3󸀠-Diamino-
benzidine (DAB, Amresco, Prodotti Gianni, Milan, Italy) was
used to perform immunohistochemistry. Before adding the
mouse monoclonal antibodies SIRT-1 and Col I (Santa Cruz
Biotechnology, Texas, USA), the cells were permeabilized
with Triton 0,1% for 10 minutes and then incubated with
blocking solution for 5 minutes before adding the specific
primary antibody at appropriate dilution, for 1 hour, at room
temperature. Subsequently, the primary antibody enhancer
was added for 10 minutes and lastly the HRP Polimer Quanto
for 10 minutes. The chromogen substrate DAB was added to
the cells, monitoring staining closely. After dehydration and
mounting with DPX, cells were detected using light micro-
scopy. Digitally fixed images were produced and analyzed
using a dedicated image software (Image Pro-Premier, Im-
magini & Computer, Milan, Italy) and the Integrated Optical
Density (IOD) was measured and normalized to cell number
[30].
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Figure 1: MTT assay after 3 days of treatment with different
concentration of resveratrol for the determination of working
concentration: 1𝜇M (R1), 5 𝜇M (R5), 10 𝜇M (R10), 25 𝜇M (R25),
and 50 𝜇M (R50) in complete medium (OGM), which represent the
control. Data represent the percentage of control, ∗𝑝 < 0.05 versus
OGM, #𝑝 < 0.05 versus R5, and ∘𝑝 < 0.05 versus R10.
2.7. Alizarin Red S Staining. Thedegree of calciumdeposition
on human osteoblasts (HOB) cultured in mineralization
medium (OMM) for 21 days was determined using Alizarin
Red S staining. At the end of the treatment period, the
culture medium was removed and HOB were washed twice
with phosphate buffered saline (PBS) and fixed with 4%
paraformaldehyde for 15min. The fixed cells were then
stained with Alizarin Red S staining solution (Sigma-Aldrich,
Milan, Italy), for 45min, at room temperature in the dark.
Then the Alizarin Red S staining solution was aspirated and
cells were washed four times with distilled water. The stained
cells were dehydrated and mounted with DPX (Sigma-
Aldrich, Milan, Italy), for light microscopy detection in order
to quantify the amount of calcium deposits. Undifferentiated
HOB (without extracellular calcium deposits) were slightly
reddish, whereas mineralized osteoblasts (with extracellular
calcium deposits) were bright orange-red. Digitally fixed
images of cells were analyzed using an image analyzer (Image
Pro-Premier, Immagini & Computer, Milan, Italy) and the
Integrated Optical Density (IOD) wasmeasured and normal-
ized to cell number [30].
2.8. Statistical Analysis. The data collected were analyzed by
one-way ANOVA followed by Bonferroni test. The level of
significance was set at 5% (𝑝 < 0.05).
3. Results
3.1. MTT Colorimetric Assay Results. MTT after 3 days of
treatment with different concentration of resveratrol showed
that the best concentration was 10 𝜇M, which was the highest
concentration without cytotoxic effects and so used for the
subsequent experiments (Figure 1).
MTT after 3 days of treatment with resveratrol 10 𝜇M
(R10), CGF and bisphosphonates alone and used in combina-
tion, showed different results (Figure 2). Treatment with R10
significantly affected osteoblast proliferation (133,1%) with
respect to complete medium (OGM) alone (100%), which
represents the control. On the contrary, treatment with alen-
dronate 5 𝜇M(AL5: 67,3%), zoledronate 5 𝜇M(ZOL5: 80,4%),
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Figure 2:MTT assay after 3 days of treatment: resveratrol 10 𝜇M(R10), alendronate 5 𝜇M(AL5), zoledronate 5 𝜇M(ZOL5), alendronate 5 𝜇M
and resveratrol 10𝜇M (AL5 + R10), and zoledronate 5 𝜇Mand resveratrol 10 𝜇M (ZOL5 + R10) in complete medium (OGM), which represent
the control; Concentrated Growth Factors (CGF): CGF and resveratrol 10𝜇M (CGF + R10), CGF and alendronate 5 𝜇M (CGF + AL5), CGF
and zoledronate 5𝜇M (CGF + ZOL5), CGF and alendronate 5 𝜇Mand resveratrol 10 𝜇M (CGF + R10 + AL5), and CGF and zoledronate 5𝜇M
and resveratrol 10 𝜇M (CGF + R10 + ZOL5). Data represent the percentage of control, ∗𝑝 < 0,05 and in particular ∘𝑝 < 0,05 versus OGM;
#𝑝 < 0,05 versus R10, AL5, ZOL5, AL5 + R10, ZOL5 + R10.
AL5 + R10 (69,5%), and ZOL5 + R10 (85%) did not sig-
nificantly increase osteoblasts proliferation with respect to
OGM alone or supplemented with R10. With the use of CGF,
alone and combined with R10 and/or bisphosphonates, the
results significantly changed. In fact, treatments with CGF
(410,8%), CGF + R10 (428,4%), and CGF + AL5 (367,4%)
significantly increased cell proliferation and those were sta-
tistically different compared with OGM, R10, AL5, ZOL5,
AL5 + R10, and ZOL5 + R10. Costimulation with CGF +
ZOL5 showed the highest percentage of cell vitality (535,3%)
and it was statistically different with respect to all previous
treatments with the exclusion of CGF, CGF + R10, and CGF +
AL5. In CGF + R10 + AL5, the percentage of cell vitality
was slower (296,2%) with respect to the other treatments
with CGF but it was statistically different with respect to
all treatments. On the contrary, using CGF and R10 in the
presence of ZOL5 (CGF + R10 + ZOL5), cell proliferation
significantly increased (487,4%), being statistically different
with respect to all treatments, except CGF, CGF + R10, and
CGF + ZOL5.
3.2. Enzyme Linked Immunosorbent Assay (ELISA) for Osteo-
protegerin (OPG) and Bone Morphogenetic Protein-2 (BMP-
2). ELISA for osteoprotegerin (OPG) (Figures 3(a) and 3(b))
and bone morphogenetic protein-2 (BMP-2) (Figures 4(a)
and 4(b)) after 3 and 21 days of culture showed different
results. Both OPG and BMP-2 showed a different trend after
3 days in OGM (complete medium) and 21 days in OMM
(mineralization medium).
As regards OPG after 3 days (Figure 3(a)), its levels
increased in cells treatedwith resveratrol 10 𝜇M(R10: 19,50 ng
± 0,70), CGF + R10 (21,03 ng ± 0,4), and CGF + alendronate
5 𝜇M (AL5) (19,5 ng ± 1,80), with respect to untreated cells,
cultured in complete medium alone (OGM: 17,59 ng ± 0,80).
Treatment with CGF + zoledronate 5 𝜇M (ZOL5) led to a
significant decrease (13,70 ng ± 2,30) with respect to R10,
CGF + R10, and CGF + AL5. In CGF + R10 + AL5, OPG
levels slightly increased (16,90 ng ± 1,50) compared with
CGF + ZOL5 but they were lower with respect to the other
experimental conditions. On the contrary, the highest OPG
concentration was observed in cells treated with CGF +R10 +
ZOL5 (22,3 ng ± 3,70) and it was statistically significant with
respect to CGF + ZOL5.
After 21 days in mineralization medium (OMM), OPG
levels showed a different trend (Figure 3(b)), reaching a
significant increase in cells treated with CGF (20,50 ng ±
1,80), CGF + R10 (24,50 ng ± 1,3), R10 + ZOL5 (18,90 ng ±
1,90), and CGF + R10 + ZOL5 (23,03 ng ± 2,00). All these
treatments were statistically different compared with con-
trol, OMM (11,70 ng ± 1,1) and OMM + R10 (10,30 ng ±
0,90). Moreover, treatments with OMM + R10 + ZOL5 and
OMM + CGF + R10 + ZOL5 were statistically different also
compared with OMM + CGF + R10 and OMM + R10 +
ZOL5. Treatments with OMM + R10 + AL5 (11,50 ng ± 1,05)
and OMM + CGF + R10 + ZOL5 (12,60 ng ± 1,15) led to
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Figure 3: Cumulative osteoprotegerin (OPG, ng) release after 3 days (a) and 21 days (b) of culture. (a) The cells were cultured in
complete medium (OGM) or Concentrated Growth Factor (CGF), which represents the controls, and in presence of resveratrol 10𝜇M
(R10), alendronate 5 𝜇M (AL5), zoledronate 5 𝜇M (ZOL5), alendronate 5 𝜇M and resveratrol 10 𝜇M (AL5 + R10), and zoledronate 5 𝜇M and
resveratrol 10𝜇M (ZOL5 + R10). The values are reported as total amount of OPG released ± SE, ∗𝑝 < 0,05 and in particular ∘𝑝 < 0,05 versus
OGM; {𝑝 < 0,05 versus OGM + R10. (b) The cells were cultured in mineralization medium (OMM) also supplemented with Concentrated
Growth Factor (OMM+CGF), which represents the controls, and in presence of resveratrol 10𝜇M(R10), alendronate 5 𝜇M(AL5), zoledronate
5 𝜇M (ZOL5), alendronate 5 𝜇M and resveratrol 10 𝜇M (AL5 + R10), and zoledronate 5 𝜇M and resveratrol 10𝜇M (ZOL5 + R10). The values
are reported as total amount of OPG released ± SE, ∗𝑝 < 0,05 and in particular ∘𝑝 < 0,05 versus OMM; #𝑝 < 0,05 versus OMM + CGF; {𝑝 <
0,05 versus OMM + R10; z𝑝 < 0,05 versus OMM + CGF + R10.
a significant decrease in OPG levels, compared with OMM +
CGF, OMM+CGF + R10, and in the case of the second treat-
ment (OMM+ CGF + R10 + ZOL5), also with OMM+ R10 +
ZOL5.
As regards BMP-2, after 3 days of culture (Figure 4(a))
its levels progressively increased in cells treated with CGF
(44,00 pg ± 4,00) and with CGF + R10 (73,30 pg ± 6,65). In
fact, both treatments were statistically different with respect
to OGM (9,13 pg ± 0,85) and costimulation with CGF + R10
resulted statistically different also compared with R10
(20,13 pg ± 1,85). Cotreatment with CGF + AL5 led to a signi-
ficant decrease in BMP-2 levels (12,7 pg ± 1,21) with respect to
CGF + R10. On the contrary, cotreatment with CGF + ZOL5
led to the highest increase in BMP-2 levels (203,50 pg± 18,50),
being statistically different with respect to OGM, R10, CGF,
CGF + R10, and CGF + AL5. Also, costimulation with CGF +
R10 + AL5 led to a significant increase in BMP-2 levels being
statistically different compared with all treatments. Similarly,
cotreatment with CGF + R10 + ZOL5 significantly increased
BMP-2 levels, being statistically different with respect to all
treatments, except that with CGF + R10.
After 21 days of culture in mineralization medium
(OMM), BMP-2 showed a different trend (Figure 4(b)) with
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Figure 4: Cumulative bonemorphogenetic protein-2 (BMP-2, pg) release after 3 days (a) and 21 days (b) of culture. (a)The cells were cultured
in complete medium (OGM) or Concentrated Growth Factor (CGF), which represents the controls, and in presence of resveratrol 10𝜇M
(R10), alendronate 5 𝜇M (AL5), zoledronate 5 𝜇M (ZOL5), alendronate 5 𝜇M and resveratrol 10 𝜇M (AL5 + R10), and zoledronate 5 𝜇M and
resveratrol 10 𝜇M (ZOL5 + R10).The values are reported as total amount of BMP-2 released ± SE, ∗𝑝 < 0,05 and in particular ∘𝑝 < 0,05 versus
OGM; #𝑝 < 0,05 versus CGF; {𝑝 < 0,05 versus OGM+R10; z𝑝 < 0,05 versus CGF + R10. (b)The cells were cultured inmineralizationmedium
(OMM) also supplemented with Concentrated Growth Factor (OMM + CGF), which represents the controls, and in presence of resveratrol
10 𝜇M (R10), alendronate 5 𝜇M (AL5), zoledronate 5 𝜇M (ZOL5), alendronate 5 𝜇Mand resveratrol 10 𝜇M (AL5 + R10), and zoledronate 5 𝜇M
and resveratrol 10 𝜇M (ZOL5 + R10). The values are reported as total amount of BMP-2 released ± SE, ∗𝑝 < 0,05 and in particular ∘𝑝 < 0,05
versus OMM; #𝑝 < 0,05 versus OMM + CGF; {𝑝 < 0,05 versus OMM + R10; z𝑝 < 0,05 versus OMM + CGF + R10.
respect to that after 3 days in OGM. BMP-2 levels pro-
gressively increased reaching a significant augment after
treatment with OMM + CGF (139,20 pg ± 12,70) that was
statistically different with respect to OMM (102,70 pg ± 9,30)
and OMM + CGF (121 pg ± 11). Cotreatment with OMM +
CGF + R10 led to a significant decrease (91,60 pg ± 8,35)
in BMP-2 levels, with respect to OMM + R10 and OMM +
CGF. Similarly, also costimulation with OMM + R10 + AL5
significantly reduced BMP-2 levels (95,40 pg ± 8,70) being
statistically different compared with OMM + CGF. Also,
treatment with OMM + R10 + ZOL5 significantly decreased
BMP-2 levels (56,80 pg ± 5,20) and this reduction was
statistically different with respect to all treatments. On the
contrary, after costimulation with OMM+CGF + R10 + AL5,
BMP-2 levels increased (111,90 pg ± 10,00), being statistically
significant compared with OMM + R10 + ZOL5. Using CGF
+ R10 + ZOL5, BMP-2 levels slightly decreased with respect
to OMM + CGF + R10 + AL5 (86,36 pg ± 4,70), being statis-
tically different with respect to OMM + R10, OMM + CGF
and OMM + R10 + ZOL5.
3.3. Immunohistochemistry for Sirtuin 1 (SIRT-1) and Collagen
Type I (Col I). Immunohistochemistry for sirtuin 1 (SIRT-1)
(Figure 5) and collagen type I (Col I) (Figure 6) on osteoblasts
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Figure 5: Quantitative evaluation of sirtuin 1 (SIRT-1) immunopositivity in osteoblasts (HOB) after 3 days of culture as IOD (Integrated
Optical Density). A micrograph as an example has been reported. The cells were cultured in complete medium (OGM) or Concentrated
Growth Factor (CGF), which represents the controls, and in presence of resveratrol 10 𝜇M (R10), alendronate 5 𝜇M (AL5), zoledronate 5𝜇M
(ZOL5), alendronate 5 𝜇M and resveratrol 10 𝜇M (AL5 + R10), and zoledronate 5 𝜇M and resveratrol 10 𝜇M (ZOL5 + R10). Data represent
means ± SE, ∗𝑝 < 0,05 and in particular ∘𝑝 < 0,05 versus OGM; #𝑝 < 0,05 versus CGF; {𝑝 < 0,05 versus OGM + R10; z𝑝 < 0,05 versus CGF
+ R10.
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Figure 6: Quantitative evaluation of collagen type I (Col I) immunopositivity in osteoblasts (HOB) after 3 days of culture as IOD (Integrated
Optical Density). A micrograph as an example has been reported. The cells were cultured in complete medium (OGM) or Concentrated
Growth Factor (CGF), which represents the controls, and in presence of resveratrol 10 𝜇M (R10), alendronate 5 𝜇M (AL5), zoledronate 5𝜇M
(ZOL5), alendronate 5 𝜇M and resveratrol 10 𝜇M (AL5 + R10), and zoledronate 5 𝜇M and resveratrol 10 𝜇M (ZOL5 + R10). Data represent
means ± SE, ∗𝑝 < 0,05 and in particular ∘𝑝 < 0,05 versus OGM; #𝑝 < 0,05 versus CGF; {𝑝 < 0,05 versus OGM + R10; z𝑝 < 0,05 versus CGF
+ R10.
has been evaluated in the cytoplasm after 3 days of treatment
and showed a similar trend.
As regards SIRT-1, treatment with resveratrol 10 𝜇M
(R10), CGF and R10 + CGF upregulated its expression, com-
pared with complete medium (OGM) alone, which repre-
sents the control. Also combined treatment with CGF and
R10 on osteoblasts treated with zoledronate 5 𝜇M(ZOL5) sig-
nificantly increased SIRT-1 expression, being statistically dif-
ferent with respect to all treatments, except that with CGF +
R10. On the contrary, costimulation with CGF and bisphos-
phonates significantly reduced SIRT-1 expressionwith respect
to the other treatments. Also, the combined use of CGF
and R10 on osteoblasts treated with alendronate 5𝜇M (AL5)
markedly reduced SIRT-1 expression compared with other
treatments, except that with CGF + AL5 in which the SIRT-1
expression was significantly increased.
Immunohistochemical analysis for Col I showed that
treatment with CGF and CGF + R10 progressively increased
Col I expression. In particular, costimulation with CGF and
R10 significantly increased Col I compared with OGM, R10,
and CGF. On the contrary, the use of R10 did not affect Col I
expression that was similar to that of OGM. The addition of
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Figure 7: Alizarin Red S staining on osteoblast (HOB) after 21 days
of culture as IOD (Integrated Optical Density). A micrograph as an
example has been reported.The cells were cultured inmineralization
medium (OMM), which represents the control, and in presence
of resveratrol 10 𝜇M (R10), alendronate 5 𝜇M (AL5), zoledronate
5 𝜇M (ZOL5), alendronate 5 𝜇M and resveratrol 10 𝜇M (AL5 + R10),
and zoledronate 5𝜇M and resveratrol 10𝜇M (ZOL5 + R10). Data
represent means ± SE, ∗𝑝 < 0,05 and in particular ∘𝑝 < 0,05 versus
OMM; z𝑝 < 0,05 versus OMM + R10.
CGF to osteoblasts treated with AL5 and ZOL5 significantly
reduced Col I levels with respect to osteoblasts treated with
CGF and/or CGF + R10. Treatment with CGF + R10 + ZOL5
positively affects Col I expression, being statistically different
compared with CGF + AL5. Contrarily, treatment with CGF
+ R10 + AL5 significantly reduced Col I levels compared with
CGF, CGF + R10, and CGF + R10 + ZOL5.
3.4. Alizarin Red S Staining. Alizarin Red S staining was
performed on osteoblasts in mineralization medium (OMM)
for 21 days in order to evaluate the degree of calcium depo-
sition. Here, we only report the data obtained for osteoblasts
cultured with OMM and also treated with resveratrol 10 𝜇M
(R10) (Figure 7) because of the cells treated for 21 days
with CGF presenting a red coated surface probably due to
haemoglobin deposits which could compromise the correct
calcium deposit detection. Results obtained showed that
treatmentwithR10 significantly increased calciumdeposition
with respect to OMM alone.
4. Discussion
The aim of the present study was to evaluate if in vitro
treatment with the naturally occurring phytoestrogen resver-
atrol and/or the platelet concentrate CGF could positively
influence humanosteoblasts proliferation and differentiation.
Moreover, we aimed to also investigate whether they could
have a protective effect on osteoblasts treated with bisphos-
phonates. In fact, the first consequence of bisphosphonates
chronic administration is a progressive bone degeneration
and cellular necrosis at the level of the maxillofacial region,
known as bisphosphonate-related osteonecrosis of the jaw or
BRONJ [1–3].
The first finding emerging from the present work is
that treatment with resveratrol positively affects cell vitality
and proliferation. This result is in agreement with previous
published data [15, 26, 33] according towhich resveratrol pro-
motes bone formation by enhancing the osteoblasts activity
and stimulating the osteoblasts proliferation and differentia-
tion. Also, Lin and colleagues [35] showed that daily intake
of resveratrol had a beneficial effect on bone turnover in
ovariectomized rats, preventing bone loss and suggesting a
positive effect of this compound on postmenopausal osteo-
porosis prevention. Similarly, Feng and collaborators [36]
suggest a beneficial effect of resveratrol against osteoporosis.
Another important finding emerging from this study is
that cotreatment with the platelet concentrate CGF and
resveratrol positively influences osteoblasts proliferation and
differentiation. In fact, both MTT assay and the evaluation
of some osteogenic markers using ELISA and immunohis-
tochemical analysis show a significant osteogenic effect in
the presence of CGF and resveratrol 10 𝜇M (R10). Moreover,
this treatment seems to have a protective role on osteoblasts
treated with bisphosphonates and in particular with the
bisphosphonate zoledronate at the final concentration of
5 𝜇M (ZOL5). In fact, MTT assay, ELISA for osteoprotegerin
(OPG) after both 3 and 21 days, and immunohistochemistry
for sirtuin 1 (SIRT-1) and collagen type I (Col I) show this
effect. Regarding bone morphogenetic protein-2 (BMP-2),
the treatments with alendronate at the final concentration of
5 𝜇M (AL5) or zoledronate at the final concentration of 5𝜇M
(ZOL5) alone always decreased BMP-2 production at both 3
and 21 days. Moreover, comparing the effects of alendronate
and zoledronate on BMP-2 release in different conditions
is possible to observe some different results reflecting a
different influence of these molecules on osteoblasts. In
addition, alendronate and zoledronate influenced differently
the osteoblasts cultured in proliferating medium (OGM)
with respect to the osteoblasts cultured in differentiating
medium (OMM). So, these two factors concurred in the
BMP-2 production. At 21 days, R10 was not able to reverse
the negative effect of alendronate at the final concentration
of 5 𝜇M (AL5) and zoledronate, at the final concentration
of 5 𝜇M (ZOL5); only the use of CGF promoted BMP-2
production. Moreover, a possible explanation for the inhi-
bition of BMP-2 production adding resveratrol 10 𝜇M (R10)
to zoledronate at the final concentration of 5𝜇M (ZOL5)
plus CGF at 3 days could be related to the balance of the
extreme greater enhancement due to CGF addition alone.
Moreover, the use of CGF is able to enhance the release of
BMP-2 more after 21 days than 3 days with alendronate at
the final concentration of 5𝜇M(AL5), while with zoledronate
at the final concentration of 5 𝜇M (ZOL5) the release is
enhanced after 3 days with respect to 21 days. Other recent
investigation revealed that the suppression of differentiation
by zoledronate was associated with decreased expression of
BMP-2 and downregulation of the phosphorylation levels in
the downstream extracellular signal-regulated kinase 1/2 and
p38 pathways [37]. A possible explanation of these results is
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that the osteogenic effect of resveratrol is probably potenti-
ated by the addition of CGF, containing autologous osteo-
inductive growth factors derived from platelets. In particular,
it contains and releases some of the principal growth factors
involved in bone regeneration, such as bone morphogenetic
proteins (BMP), especially BMP-2 and BMP-7, but also TGF-
𝛽1, PDGF-AB, IGF-1, VEGF, and TNF-𝛼 [8]. Several studies,
both in vivo and in vitro [38–40], suggest that CGF promotes
bone regeneration. Our data show that, in the presence of
the bisphosphonate alendronate at the final concentration of
5 𝜇m (AL5), cotreatment with CGF and R10 showed a less
pronounced effect except that for BMP-2 release after both
3 and 21 days. In this context, it is important to underline that
the exact molecular mechanism of bisphosphonate action is
not clear andneeded to be further investigated. In fact, several
studies have evaluated the effect of alendronate, zoledronate,
and other bisphosphonates on osteoblasts proliferation, mat-
uration, and differentiation, obtaining controversial results,
depending also on the type of bisphosphonate used as well
as on the applied concentration. Koch and colleagues [41]
reported an antiproliferative effect of bisphosphonates on
osteoblasts, similarly to our MTT results in which bisphos-
phonates had no significant proliferative effect with respect
to OGM and R10. In a similar way, also Garc´ıa-Moreno
and collaborators [42] reported that alendronate at high
concentrations (>10−5M) inhibited osteoblasts proliferation,
whereas at low concentrations (≤10−5M) it did not signifi-
cantly affect osteoblast proliferation compared with controls.
Also, Huang and colleagues [43] showed that zoledronate at
the micromolar level inhibited osteoblasts proliferation and
matrix mineralization. On the contrary, other works [44, 45]
suggested that bisphosphonates may stimulate proliferation
of osteoblasts and inhibit osteocytes and osteoblasts apopto-
sis. Also, Im and colleagues [46] showed that alendronate and
risedronate promoted proliferation and maturation of both
primary osteoblasts and MG-63 osteoblast-like cells.
The second step of the present study was to evaluate the
in vitro effect of R10, CGF, and cotreatment with both R10
and CGF on the expression of some markers of osteogenesis
such as OPG, BMP-2, SIRT-1, and Col I. As regards OPG,
bisphosphonates interfere with bone remodeling processes
which are controlled by specific mediators such as RANKL,
RANK, and OPG. ELISA results showed a different trend in
OPG expression after 3 days and 21 days of culture. After 3
days, the highest amount in OPG levels was observed after
cotreatment with CGF + R10 + ZOL5 whereas after 21 days in
mineralizationmedium,OPG levels significantly increased in
osteoblast treated with CGF, CGF + R10, R10 + ZOL5, and
CGF + R10 + ZOL5. These results suggest that R10 and/or
CGF also combined with ZOL5 have a positive effect on
both osteoblast proliferation and differentiation. Similarly,
Koch and colleagues [47] reported that OPG expression
was moderately enhanced by zoledronate and ibandronate,
after an experimental period of 14 days. Also, the study of
Viereck and collaborators [48] reported a significant increase
in OPG after 3 days of treatment with zoledronate. Treatment
with alendronate instead did not significantly change OPG
levels after 3 days of culture but it significantly reduced OPG
expression after 21 days in mineralization medium (OMM)
in the presence of R10 and/or CGF. These data were in
concordance with those reported by Lin and colleagues [49]
that did not find a significant influence on OPG expression
by alendronate and pamidronate, after 2 days of treatment.
Also, in another work [50], it was reported that treatment
with alendronate for 24 hours did not have effect on OPG
secretion. Given the importance of BMP-2 in osteoblastic
differentiation, the present study investigated whether in
vitro treatment with resveratrol and/or CGF influences the
expression of BMP-2. BMP-2 expression showed a different
trend after 3 days or 21 days of culture. After 3 days, the
highest levels of BMP-2 were detected in cells treated with
CGF + ZOL5. Also, cotreatment with CGF + R10 + AL5
and CGF + R10 + ZOL5 increased BMP-2 levels with respect
to all treatments, with the exception of CGF + ZOL5. In
literature there are different results, which should be clarified.
In fact, Ribeiro and colleagues [51] showed an increase
of BMP-2 expression with alendronate and zoledronate in
cocultured human endothelial and mesenchymal stem cells.
Another study [52] demonstrated that in vitro zoledronate
treatment resulted in a significant upregulation of BMP-2
gene expression, in human osteoblast cells. On the contrary,
Huang and colleagues [37] showed that treatment with
zoledronate at concentrations ≤ 1 𝜇M significantly decreased
BMP-2 expression in a concentration-dependent manner,
following 7 days of treatment. After 21 days of treatment
in mineralization medium (OMM), high levels of BMP-2
were found in cells treated with CGF alone and combined
with R10 and bisphosphonates (AL5 and ZOL5), suggesting
that these treatments influenced osteoblast differentiation.
As regards CGF, Borsani and collaborators [8] showed that
BMP-2 present in this platelet preparation had a slow kinetic
release, with a linear increase from 6th day and reaching
the maximum accumulation at the end of the experimental
period of 8 days. So, probably CGF contributed to osteoblast
differentiation. Another study [53] reported that alendronate
treatment for 14 days enhanced the differentiation of MG-63
cells, suggesting its role in osteogenic differentiation.
Resveratrol is considered to be an activator of SIRT-1.
In fact, Feng and collaborators [36] showed that resveratrol
treatment significantly increased the expression of SIRT-1 in
a rat model of osteoporosis. Similarly, Zhang and colleagues
[54] demonstrated that resveratrol promoted osteoblast pro-
liferation and differentiation by activating SIRT-1. Also,
another recent study [23] showed that resveratrol upregulated
SIRT-1 levels. Similarly, also results obtained in the present
study demonstrated that treatment with resveratrol signifi-
cantly enhanced SIRT-1 expression, so promoting osteoblast
proliferation and differentiation. As showed also treatment
with CGF, CGF + R10, and CGF + R10 + ZOL5 significantly
increased SIRT-1 levels suggesting that both R10 and CGF
may have a protective role on human osteoblasts treated with
ZOL5. Similar results were obtained for Col I.
However, the strong limitation of the present study was
the deposits observed after the treatment with CGF for 21
days. In fact, this periodwas too long and the poor availability
of donors did not allow replacing CGF more frequently to
avoid deposits on cell surface which were not optimal for
cell analysis. For this reason, for Alizarin Red staining, we
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reported data obtained after 21 days of treatment without
CGF. Nevertheless, we monitored a recognised marker of
osteoblast differentiation, OPG, which could be indicative of
in vitro bone formation as the alkaline phosphatase (ALP).
Indeed, OPG plays a critical role in the regulation of bone
turnover [28] and ALP were upregulated in the OPG overex-
pressing cells [55] demonstrating the link between these two
molecules during bone deposition. Moreover, BMP-2 is one
of the most investigated BMP family members and has been
identified as the most potent inducer of osteogenesis [29].
5. Conclusion
Taken together, the results of this study confirmed that the
treatment with resveratrol promotes in vitro osteoblast pro-
liferation and differentiation. Moreover, also treatment with
CGF and cotreatment with resveratrol and CGF have a
protective role on human osteoblasts treated with bisphos-
phonates and in particular with zoledronate. The use of anti-
oxidants in tissue regeneration has been previously explored,
such as the use of platelet concentrates; nevertheless their
synergistic effect has been less investigated. Our experiments
suggest that the effects of resveratrol on CGF against bisphos-
phonates-induced side effects are not always synergic and
depend on experimental conditions, but resveratrol actually
functions as a modulator of CGF effects. These results could
be promised in the pathogenesis of BRONJ even if further in
vivo studies are needed in order to confirm and validate these
results.
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